Results 161 to 170 of about 17,710 (254)

Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies. [PDF]

open access: yesDermatol Ther (Heidelb)
Kwatra SG   +9 more
europepmc   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda   +31 more
wiley   +1 more source

Dupilumab in patients with cold urticaria: Results from a phase 3 trial. [PDF]

open access: yesJ Allergy Clin Immunol Glob
Metz M   +9 more
europepmc   +1 more source

Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab

open access: yes
International Journal of Dermatology, EarlyView.
Joy Justice   +3 more
wiley   +1 more source

Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This analysis used a large clinical trial data set (>30,000 patient visits across >2800 patients) and novel statistical methodologies (including frequency cross‐over analysis and means based on spline regression) to develop severity threshold bands for clinician‐ and patient‐reported outcome measures for adults with moderate‐to‐severe atopic dermatitis.
Andreas Wollenberg   +7 more
wiley   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger   +11 more
wiley   +1 more source

Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema Questionnaire

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Eric L. Simpson   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy